Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RXi Pharmaceuticals and EyeGate Pharma are set to collaborate on the ocular delivery of RNAi therapeutics.
Subscribe to our email newsletter
The collaboration will explore the use of EyeGate’s iontophoresis technology, which is currently being studied in a Phase III trial with an anti-inflammatory product (EGP-437), to deliver RXi’s sd-rxRNA compounds to the eye in preclinical models.
Iontophoresis is a method of drug delivery that uses a low-level electrical current to deliver a drug across the ocular surface into the eye.
EyeGate Pharma president and CEO Stephen From said that the collaboration with RXi will enable them to expand the drug delivery options for the EyeGate II Delivery System into RNAi therapeutics, developing new uses and markets for the device, as well as developing more patient friendly treatments for retinal disease based on RXi’s sd-rxRNA technology.
RXi president and CEO Noah Beerman said that combining their RNAi technology with EyeGate’s non-invasive ocular delivery system (EyeGate II), provides them with the potential opportunity to develop novel treatments for many ocular diseases and to improve treatment options for the ophthalmology community.